Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 February 2022 | Story NONSINDISO QWABE | Photo Thabiso Mdakana
Qwaqwa Campus vaccination drive
Andile Tshabalala and Theodore Hlalele, CSRC Qwaqwa Campus.

As the University of the Free State is encouraging staff and students to be vaccinated in order for all of us to return to campus life as we know it, the Qwaqwa Campus held its first in-person vaccination activation drive for its first and returning students. The drive was to further encourage students to vaccinate, and to keep themselves and others safe by educating themselves.

The cheerful and excited crowd of more than 100 students were gathered at the Amphitheatre on campus, where they got to know more about the COVID-19 Regulations and Required Vaccination Policy and interacted with Department of Health officials to understand more about the jabs and booster shots.

No one is forced, but everyone is encouraged

The university’s approved policy came into effect on 14 February, requiring staff and students to be vaccinated as a measure towards ensuring everyone’s smooth return to its three campuses. However, as Qwaqwa Campus Principal Dr Martin Mandew highlighted, “no one is being forced to vaccinate, but we are all strongly encouraged to do so”.

Dr Mandew said the student experience is too rich and vibrant to be confined to virtual learning. He showed students his own vaccination certificate, quoting a Zulu proverb, ‘indlela ibuzwa kwabaphambili’, which loosely translated means ‘those who have gone before you can show the way’.

“If you are not vaccinated, it will be impossible for us to enjoy face-to-face interaction again. Ask yourself: ‘If the principal is vaccinated, who am I not to be?” he said.

The lively drive also kept students entertained through live performances by local artists. 

Students could also raise pressing issues and questions with Department of Health officials – including common side effects, apathy against vaccination due to religious beliefs, the efficacy of the vaccine to protect against COVID-19, and the implementation of the UFS Vaccination Policy. 

The programme line-up also included messages of support from the Director: Student Affairs, Zoleka Dotwana, the Deputy Director of Housing and Residences, Zakhele Mdluli, and UVPERSU Vice-Chairperson, Dr Grey Magaiza.

The operating days of the on-campus vaccination site have been extended to accommodate streams of incoming students who still want to be vaccinated. 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept